A recent study showed that rates of antiretroviral therapy in enrollees living with HIV increased over the years, but women ...

Umuti Cabotegravir utangwa mu rushinge rimwe mu mezi abiri, uherutse kuvugwa ko washitse mu Rwanda, umuhinga aragabisha ...

As the new cases and related deaths fall in sub-Saharan Africa, the virus is rearing its head elsewhere. What's the cause?

Merck's experimental two-drug combination met the main goal of significantly suppressing replication of the HIV-1 virus in ...

The NACA boss said this while urging Nigerians to prioritise their health by knowing their HIV status, especially as the ...

U.S. drugmaker Merck said on Thursday its experimental combination treatment for some adults with HIV-1 infection met the ...

As we mark the holidays, here are a few of the many heroes who are working to build a stronger global health future by ...

Assia Ezzahraoui, 25, a participant in Tibu Africa’s Sports Vocational School program, reflects: “HIV awareness was a ...

Merck (MRK) stock in focus as company reports mixed results in Phase 3 trials for HIV therapy islatravir in combination with ...

There is hope for a new 5 by 3 global target of getting 5 million people on long-acting PrEP to prevent HIV by 2030.

Gilead Sciences will no longer provide four HIV medicines for free as part of a patient assistance program starting at the ...